

Claims

1. A peptide comprising an amino acid sequence of SEQ ID No. 14, wherein said peptide has an overall length of from 9 to 16 amino acids, and wherein said peptide binds to molecule(s) of the major histocompatibility complex (MHC) and/or induces T cells cross-reacting with said peptide; and a pharmaceutical acceptable salt thereof.
2. The peptide according to claim 1, wherein said peptide consists of the amino acid sequence of SEQ ID No. 14.
3. The peptide according to claim 1 or 2, wherein said peptide includes non-peptide bonds.
4. The peptide according to any one of claims 1 to 3, wherein said peptide is part of a fusion protein comprising N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii).
5. An isolated antibody, in particular a soluble or membrane-bound antibody, that specifically recognizes the peptide according to any of claims 1 or 2 when bound to an MHC molecule.
6. A recombinant, soluble or membrane-bound T-cell receptor that is reactive with an HLA ligand, wherein said ligand consists of SEQ ID No. 14.
7. The T-cell receptor according claim 6, wherein said T-cell receptor is provided as a soluble molecule and optionally carries a further effector function, such as an immune stimulating domain or toxin.
8. A nucleic acid, encoding for a peptide according to any one of claims 1 to 5, or encoding for a TCR according to claim 6 or 7, optionally linked to a heterologous promoter sequence.
9. An expression vector expressing the nucleic acid according to claim 8.
10. A recombinant host cell comprising the peptide according to any one of claims 1 to 4, the nucleic acid according to claim 8 or the expression vector according to claim 9, wherein said host cell for example is an antigen presenting cell such as a dendritic cell, or wherein said host cell for example is a T cell or NK cell.

11. A method for producing the peptide according to any one of claims 1 to 4, or the TCR according to claim 6 or 7, said method comprising culturing a host cell according to Claim 10, and isolating said peptide or TCR from said host cell and/or its culture medium.

12. An *in vitro* method for producing activated T lymphocytes, the method comprising contacting *in vitro* T cells with antigen loaded human class I MHC molecules expressed on the surface of a suitable antigen-presenting cell or an artificial construct mimicking an antigen-presenting cell for a period of time sufficient to activate said T cells in an antigen specific manner, wherein said antigen is a peptide according to claim 1 or 2.

13. An isolated activated T lymphocyte, produced by the method according to claim 12 that selectively recognizes a cell which presents a polypeptide comprising an amino acid sequence given in claim 1 or 2.

14. The peptide according to any one of claims 1 to 4, the antibody according to claim 5, the TCR according to claim 6 or 7, the nucleic acid according to claim 8, the expression vector according to claim 9, or the host cell according to claim 10 for use in medicine.

15. Use of the peptide according to any one of claims 1 to 4, the antibody according to claim 5, the TCR according to claim 6 or 7, the nucleic acid according to claim 8, the expression vector according to claim 9, the host cell according to claim 10, or the activated T lymphocyte according to claim 13 in the manufacture of a medicament for the treatment of cancer.

16. The use according to claim 15, wherein said cancer is selected from the group of hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, non-small cell lung cancer (NSCLC), pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer, chronic lymphocytic leukemia (CLL), Merkel cell carcinoma (MCC), small cell lung cancer (SCLC), Non-Hodgkin lymphoma (NHL), acute myeloid leukemia (AML), gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), uterine cancer (UEC), and other tumors that show an overexpression of a protein from which the peptide SEQ ID No. 14 is derived from.

17. A kit comprising:

- a) a container comprising a pharmaceutical composition containing the peptide according to any one of claims 1 to 4, the antibody according to claim 5, the TCR according to claim 6 or 7, the nucleic acid according to claim 8, the expression vector according to claim 9, the host cell according to claim 10, or the activated T lymphocyte according to claim 13, in solution or in lyophilized form;
- b) optionally, a second container containing a diluent or reconstituting solution for the lyophilized formulation; and
- c) optionally, instructions for (i) use of the solution or (ii) reconstitution and/or use of the lyophilized formulation.

18. The kit according to claim 19, further comprising one or more of (iii) a buffer, (iv) a diluent, (v) a filter, (vi) a needle, or (v) a syringe.

19. A pharmaceutical composition comprising at least one active ingredient selected from the group consisting of the peptide according to any one of claims 1 to 4, the antibody according to claim 5, the TCR according to claim 6 or 7, the nucleic acid according to claim 8, the expression vector according to claim 9, the host cell according to claim 10, or the activated T lymphocyte according to claim 13, and a pharmaceutically acceptable carrier, and optionally additional pharmaceutically acceptable excipients and/or stabilizers.